Fusarochromanone is a mycotoxin produced by Fusarium species, particularly Fusarium proliferatum. It exhibits potent cytotoxic activity against various cancer cell lines, including leukemia, colon, and breast cancer cells. Its mechanism of action involves the induction of apoptosis and cell cycle arrest. Fusarochromanone has also been shown to possess antimicrobial activity against bacteria and fungi. Its structural features, particularly the presence of a chromone ring and a hydroxyl group, contribute to its biological activity. Studies on fusarochromanone focus on understanding its biosynthesis, toxicological effects, and potential therapeutic applications, particularly in cancer treatment. The compound has been shown to be a potent inhibitor of tumor angiogenesis, suggesting its potential as an anti-cancer drug.'
fusarochromanone: from Fusarium sp.; consists of an amino acid bearing chromone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 107777 |
| CHEBI ID | 174090 |
| SCHEMBL ID | 4475170 |
| MeSH ID | M0153910 |
| Synonym |
|---|
| 5-amino-6-(3-amino-4-hydroxybutanoyl)-2,2-dimethyl-3h-chromen-4-one |
| 104653-89-6 |
| CHEBI:174090 |
| nsc627608 |
| fusarochromanone |
| 5-amino-6-(3-amino-4-hydroxybutanoyl)-2,2-dimethyl-2,3-dihydro-4h-chromen-4-one |
| 5-amino-6-(3-amino-4-hydroxy-butanoyl)-2,2-dimethyl-chroman-4-one |
| tdp 1 |
| unii-fm54x8s89o |
| fm54x8s89o , |
| tdp-1 |
| fusarochromenone |
| 4h-1-benzopyran-4-one, 5-amino-6-(3-amino-4-hydroxy-1-oxobutyl)-2,3-dihydro-2,2-dimethyl- |
| 5-amino-6-(3-amino-4-hydroxy-1-oxobutyl)-2,3-dihydro-2,2-dimethyl-4h-1-benzopyran-4-one |
| SCHEMBL4475170 |
| fusarochromanone, (+/-)- |
| 5-amino-6-(3-amino-4-hydroxybutanoyl)-2,2-dimethyl-3,4-dihydro-2h-1-benzopyran-4-one |
| 5-amino-6-(3-amino-4-hydroxy-1-oxobutyl)-2,3-dihydro-2,2-dimethyl-4h-1-benzopyran-4-one, 9ci |
| Q27278066 |
| DTXSID20909102 |
| AKOS040739323 |
| compound np-008475 |
Fusarochromanone (FC101) is a small molecule fungal metabolite with a host of interesting biological functions, including very potent anti-angiogenic and direct anti-cancer activity. Fusarium equiseti is implicated in the poultry disease tibial dyschrondroplasia.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fusarochromanone (FC101) is a small molecule fungal metabolite with a host of interesting biological functions, including very potent anti-angiogenic and direct anti-cancer activity." | ( Biological activities of fusarochromanone: a potent anti-cancer agent. Adelmund, S; Barzegar, M; Bhinge, KN; Clifford, JL; Furmanski, BD; Gu, Y; Huang, S; Kevil, CG; Kim, YJ; Kolluru, GK; Liu, YY; Mahdavian, E; Palyok, P; Quick, Q; Salvatore, BA; Williams-Hart, T; Wu, Y, 2014) | 2.15 |
| "Fusarochromanone is a toxic metabolite produced by Fusarium equiseti, a fungus present in decaying cereal plants in northern latitudes; it has been detected in various food grains. " | ( Inhibitory effects of fusarochromanone on melanoma growth. Culberson, C; Dréau, D; Foster, M; Hogg, M; Nunes, P; Wuthier, RE, 2007) | 2.1 |
| "Fusarochromanone is a mycotoxin produced by Fusarium equiseti that is implicated in the poultry disease tibial dyschrondroplasia. " | ( Mass spectral analysis and fragment ion structure of fusarochromanone. Mirocha, CJ; Pawlosky, RJ, 1991) | 1.97 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Fusarochromanone has been shown to have both stimulatory and inhibitory effects on various mammalian cells, depending on the concentration used." | ( Inhibitory effects of fusarochromanone on melanoma growth. Culberson, C; Dréau, D; Foster, M; Hogg, M; Nunes, P; Wuthier, RE, 2007) | 1.38 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Further analysis of FC101's physicochemical properties using both experimentally obtained and simulated values revealed the likelihood of membrane permeation and oral bioavailability of the compound." | ( Differential uptake and selective permeability of fusarochromanone (FC101), a novel membrane permeable anticancer naturally fluorescent compound in tumor and normal cells. Dréau, D; Furmanski, BD; Fuseler, JW; Wuthier, RE, 2009) | 0.61 |
| Class | Description |
|---|---|
| 1-benzopyran | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 3 (17.65) | 29.6817 |
| 2010's | 4 (23.53) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 22 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||